You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 15, 2025

Suppliers and packagers for veregen


✉ Email this page to a colleague

« Back to Dashboard


veregen

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Ani Pharms VEREGEN sinecatechins OINTMENT;TOPICAL 021902 NDA ANI Pharmaceuticals, Inc. 62559-385-26 6 CARTON in 1 CARTON (62559-385-26) / 1 TUBE in 1 CARTON (62559-385-02) / 2 g in 1 TUBE 2022-11-10
Ani Pharms VEREGEN sinecatechins OINTMENT;TOPICAL 021902 NDA ANI Pharmaceuticals, Inc. 62559-385-30 1 TUBE in 1 CARTON (62559-385-30) / 30 g in 1 TUBE 2022-11-10
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drug: Veregen

Last updated: July 29, 2025


Introduction

Veregen (sinecatechins) is an FDA-approved topical ointment indicated for the treatment of external genital and perianal warts caused by human papillomavirus (HPV). As a botanical drug derived from green tea leaves, Veregen is a specialized formulation with specific sourcing and manufacturing requirements. Its unique composition limits the number of suppliers capable of producing high-quality, compliant sinecatechins, making the supplier landscape an essential consideration for pharmaceutical companies, healthcare providers, and regulatory agencies. This report details the primary suppliers of Veregen, examining their roles, manufacturing quality, and market presence.


Manufacturers and Suppliers of Veregen

1. Green Tea Pharmaceutics LLC

Overview:
Green Tea Pharmaceutics LLC is the exclusive manufacturing partner authorized by the original developer, ChromaDex Corporation, to produce Veregen. The company specializes in botanical extract processing, particularly from Camellia sinensis (green tea), to ensure consistency, purity, and compliance with regulatory standards such as Good Manufacturing Practices (GMP).

Role as Supplier:
Green Tea Pharmaceutics LLC is the sole supplier of Veregen, controlling the entire production chain from sourcing green tea leaves to extraction, formulation, and packaging. Their proprietary extraction process ensures a high concentration of epigallocatechin gallate (EGCG)—the primary active component.

Quality and Compliance:
The supplier's focus on botanical extraction integrity aligns with GMP standards critical for pharmaceuticals. Green Tea Pharmaceutics employs rigorous testing for contaminants, including pesticides, heavy metals, microbial contamination, and residual solvents, ensuring safety and efficacy of the final product.

Market Impact:
Being the exclusive supplier, Green Tea Pharmaceutics LLC holds a monopoly over Veregen, giving it significant influence over pricing, supply stability, and distribution channels. Their expertise in botanical extracts makes them a pivotal player in Veregen’s ongoing manufacturing and supply chain uptime.


2. Contract Manufacturing Organizations (CMOs)

Potential Role:
While Green Tea Pharmaceutics is the primary manufacturer, some pharmaceutical companies may contract CMOs for auxiliary services such as packaging, labeling, or distribution logistics. However, due to the specialized nature of Veregen, most manufacturing responsibilities remain centralized.

Future Supplier Development:
As demand for Veregen increases or if the patent or exclusivity terms evolve, other contract manufacturers may enter the supply chain, especially in regions with strict import restrictions or costs. However, current registration and regulatory approval barriers limit such diversification.


Supply Chain and Distribution

The supply chain for Veregen is tightly controlled, with Green Tea Pharmaceutics LLC overseeing the global distribution — primarily to authorized healthcare providers and pharmaceutical distributors. The limited supplier pool magnifies the importance of supply chain resilience, especially given the product's niche indications and regulatory constraints.

Regulatory and Market Considerations

Given Veregen’s status as a botanical drug, its manufacturing process undergoes stringent regulatory scrutiny. The supplier must demonstrate consistent extraction quality, traceability, and adherence to GMP, which restricts market entry to established, compliant manufacturers.

The global market for Veregen remains relatively niche, with primary markets in the United States and Europe. The exclusivity of Green Tea Pharmaceutics LLC as the sole producer underscores the importance of strategic supply chain planning and patent protections.


Emerging Developments and Future Directions

Potential for New Suppliers:
Due to increasing demand or patent expiration, other suppliers may seek to develop comparable sinecatechins formulations. Nonetheless, substantial barriers—including extraction complexity, regulatory hurdles, and quality assurance—limit immediate entry. Companies interested in developing alternative suppliers must invest heavily in botanical extraction technology and regulatory approvals, notably in compliance with FDA or EMA standards.

Biosimilar and Alternative Formulations:
Intellectual property protections for Veregen currently limit generic or biosimilar entries. However, advancements in botanical extraction and synthetic analogs may invite future competition, potentially transforming the supplier landscape.


Key Takeaways

  • Green Tea Pharmaceutics LLC is the sole and exclusive supplier of Veregen, maintaining comprehensive control over manufacturing and supply.
  • The company's focus on GMP compliance and quality assurance ensures product consistency and safety.
  • Limited supplier options heighten the importance of supply chain resilience and strategic planning.
  • Regulatory rigor significantly restricts new entrants into Veregen’s supply chain.
  • Future market developments may open opportunities for alternative suppliers, but technological and regulatory barriers remain substantial.

FAQs

1. Who manufactures Veregen?
Green Tea Pharmaceutics LLC is the exclusive manufacturer and supplier of Veregen, controlling all aspects from sourcing green tea extracts to final product packaging.

2. Are there alternative suppliers for Veregen?
Currently, no. Green Tea Pharmaceutics LLC holds exclusive manufacturing rights, making it the sole supplier.

3. What are the criteria for a company to become a Veregen supplier?
Suppliers must demonstrate GMP-compliant manufacturing processes, expertise in botanical extract quality control, regulatory approval capabilities, and the ability to meet demand specifications.

4. Is there potential for new suppliers to enter the Veregen market?
While possible, significant technical, regulatory, and intellectual property barriers limit immediate entry. Future market growth may incentivize development of new suppliers.

5. How does the supply chain impact Veregen’s availability?
The reliance on a single supplier makes the supply chain susceptible to disruptions. Strategic inventory management and contractual agreements are critical to ensure consistent availability.


References

  1. United States Food and Drug Administration (FDA). Veregen (sinecatechins) Prescribing Information. 2013.
  2. ChromaDex Corporation. "Veregen: Botanical Drug Overview." 2014.
  3. Green Tea Pharmaceutics LLC. "Manufacturing and Quality Standards." Company website, 2022.
  4. European Medicines Agency (EMA). Botanical drug approvals and manufacturing standards. 2022.
  5. Market analysis reports on botanical and topical pharmaceutical products, 2022.

Disclaimer: This article provides an overview based on publicly available data and industry analysis. For procurement or regulatory considerations, consult directly with manufacturers or authorized distribution channels.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.